Company intelligence / Profile preview

Durant & Durant

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Durant Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for difficult-to-drug oncogenic targets. The company's primary focus is on the MYC oncogene, a master regulator of cell growth and metabolism that is dysregulated in a majority of human cancers. By utilizing advanced structural biology and medicinal chemistry, Durant aims to disrupt MYC-protein interactions to induce tumor regression. The company is currently advancing its lead programs through lead optimization and early pre-clinical validation for various solid tumor indications.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Durant & Durant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Durant & Durant.

Explore the full profile